Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP ...

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

WASHINGTON — Eli Lilly's obesity ... rival Novo Nordisk's obesity drug Wegovy also gained Medicare coverage to reduce the risk of heart attacks and strokes. Lilly and Novo are testing their ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The big pharma companies Novo Nordisk and Eli Lilly look to be the main ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.

Patients who took popular weight loss drugs were 12 per cent less likely to develop Alzheimer’s disease but were more at risk ... diabetes such as Novo Nordisk’s Ozempic and Wegovy and Eli ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...